₹166.85
▲ +3.78 +2.32%
As of 23 Oct 2026 · delayed
NSE Listed
Amanta Healthcare Limited (AMANTA)
20-day avg volume: 80K shares
- Company is almost debt-free.
- Company is loss-making at the latest annual result.
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹67 Cr | ₹68 Cr | ₹72 Cr | ₹65 Cr | ₹71 Cr | ₹74 Cr | ₹77 Cr | ₹69 Cr |
| EBITDA | ₹9 Cr | ₹11 Cr | ₹14 Cr | ₹11 Cr | ₹10 Cr | ₹11 Cr | ₹12 Cr | ₹11 Cr |
| Net Profit | ₹2 Cr | ₹4 Cr | ₹6 Cr | ₹4 Cr | ₹1 Cr | ₹5 Cr | ₹6 Cr | ₹3 Cr |
| EPS | — | — | — | — | — | — | — | — |
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹187 Cr | ₹172 Cr | ₹227 Cr | ₹263 Cr | ₹282 Cr | ₹276 Cr | ₹291 Cr |
| EBITDA | ₹23 Cr | ₹22 Cr | ₹36 Cr | ₹38 Cr | ₹39 Cr | ₹43 Cr | ₹44 Cr |
| Net Profit | ₹-19 Cr | ₹-22 Cr | ₹55 Cr | ₹-2 Cr | ₹4 Cr | ₹11 Cr | ₹15 Cr |
| EPS | -7.04 | -8.14 | 20.54 | -0.79 | 1.35 | 3.71 | 4.33 |
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹388 Cr | ₹392 Cr | ₹392 Cr | ₹374 Cr | ₹352 Cr | ₹382 Cr | ₹558 Cr |
| Total Liabilities | ₹359 Cr | ₹385 Cr | ₹320 Cr | ₹311 Cr | ₹286 Cr | ₹285 Cr | ₹338 Cr |
| Equity | ₹29 Cr | ₹7 Cr | ₹72 Cr | ₹63 Cr | ₹66 Cr | ₹96 Cr | ₹220 Cr |
| Total Debt | — | — | — | — | — | — | — |
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | ₹26 Cr | ₹137 Cr | ₹49 Cr | ₹64 Cr | ₹50 Cr | ₹56 Cr |
| Investing | ₹-16 Cr | ₹-5 Cr | ₹-7 Cr | ₹-10 Cr | ₹-24 Cr | ₹-94 Cr |
| Financing | ₹-18 Cr | ₹-50 Cr | ₹-42 Cr | ₹-46 Cr | ₹-23 Cr | ₹126 Cr |
| Free Cash Flow | ₹26 Cr | ₹137 Cr | ₹49 Cr | ₹64 Cr | ₹50 Cr | ₹56 Cr |
Healthcare · Drug Manufacturers - Specialty & Generic
Amanta Healthcare Limited operates as a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products and parenteral products in Africa, Latin America, the United Kingdom, and internationally. The company manufactures its products in three product group segments Large Volume Parenteral, Nipple Head (Single Port), SteriPort (Two Ports), and Small Volume Parenteral. Additionally, it manufactures medical devices and fluid therapy - (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products, such as irrigation, first-aid solution, and eye lubricants in medical device segment. It also offers a wide range of closure systems, such as nipple head, twist-off, leur-lock, and screw types and container fill-volume ranging from 2ml to 1000 ml. Its markets its products through three strategic business units including national sales, international sales, and product partnering with various foreign and Indian pharmaceutical companies. Amanta Healthcare Limited was formerly known as Marck Biosciences Limited and changed its name to Amanta Healthcare Limited in June 2014. Amanta Healthcare Limited was incorporated in 1994 and is headquartered in Ahmedabad, India.
www.amanta.co.in ↗As of 2026-09-30
Quarterly — figures in %. Latest 10 quarters.
| Period | Sept 2024 | Feb 2025 | Jun 2025 | Aug 2025 | Aug 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 85.5% | 85.5% | 63.6% | 85.6% | 85.6% | 63.6% | 63.6% | 63.7% | 63.8% | 63.8% |
| FIIs | 0% | 0% | 2.2% | 0% | 0% | 1% | 1.1% | 0.8% | 0.4% | 0.1% |
| DIIs | 0% | 0% | 12.2% | 14.4% | 0% | 11.3% | 11.2% | 12.9% | 12.9% | 12.2% |
| Public | 14.5% | 14.5% | 22% | 0% | 14.4% | 24.1% | 24.1% | 22.6% | 22.8% | 23.9% |
| Promoter Pledge | 0% | 25.3% | 0% | 25.2% | 25.2% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 192 | 200 | 30,695 | 361 | 361 | 18,669 | 16,181 | 15,222 | 12,612 | 12,319 |
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202603 | — | — | — | — |
| Name | Category | Stake | Shares |
|---|---|---|---|
| Bhavesh Girishbhai Patel | Shareholding of Promoter and Promoter Group | 16.3% | 63,32,429 |
| Vishal Ashokkumar Patel | Shareholding of Promoter and Promoter Group | 10.1% | 39,05,288 |
| Jitendrakumar Jashbhai Patel | Shareholding of Promoter and Promoter Group | 9% | 35,02,038 |
| Milcent Appliances Private Limited | Shareholding of Promoter and Promoter Group | 8% | 31,00,000 |
| Praful Jashbhai Patel | Shareholding of Promoter and Promoter Group | 5.9% | 22,82,264 |
| Bandhan Small Cap Fund | Public Shareholding | 5.1% | 19,87,784 |
| Shailesh Mansukhlal Mehta | Shareholding of Promoter and Promoter Group | 4.5% | 17,32,763 |
| Niranjanbhai Ishwarbhai Patel | Shareholding of Promoter and Promoter Group | 3.9% | 15,04,951 |
| Kirit Ambalal Desai | Shareholding of Promoter and Promoter Group | 3.3% | 12,77,479 |
| Jayshreeben Rohitkumar Patel | Shareholding of Promoter and Promoter Group | 2.6% | 9,98,109 |
| Finavenue Capital Trust - Finavenue Growth Fund | Public Shareholding | 1.9% | 7,23,629 |
| Perpetuity Health To Wealth (h2w) Rising Fund | Public Shareholding | 1.8% | 7,10,000 |
| Aarth Aif Growth Fund | Public Shareholding | 1.6% | 6,11,000 |
| Pravinchandra Dhanjibhai Mehta | Shareholding of Promoter and Promoter Group | 0.3% | 99,600 |
| Darpana J. Patel | Shareholding of Promoter and Promoter Group | 0.1% | 25,163 |
| Sarala Kirit Desai | Shareholding of Promoter and Promoter Group | 0% | 12,024 |
| Jatin Kumar J Mehta | Shareholding of Promoter and Promoter Group | 0% | 2,000 |
| Manisha B Patel | Shareholding of Promoter and Promoter Group | 0% | 1 |
| Pramilaben Patel | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Devashish Patel | Shareholding of Promoter and Promoter Group | 0% | 0 |
| J R Mehta | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Bharati Mehta | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Veenaben Jitendrakumar Patel | Shareholding of Promoter and Promoter Group | 0% | 1 |
| Donikaben Patel | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Ashokkumar Patel | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Name | Designation | Year |
|---|---|---|
| Bhavesh Patel | Chairman & Managing Director | 2026 |
| Nimesh Patel | Non-Exec & Non-Independent Dir | 2026 |
| Kshitij Patel | Independent Non Exe. Director | 2026 |
| Anjali N. Choksi | Independent Non Exe. Director | 2026 |
| Pratik Gandhi | Non Executive Director | 2026 |
| Nitin Jain | Independent Non Exe. Director | 2026 |
| Nikhita Dinodia | Company Sec. & Compli. Officer | 2026 |
| Segment | Revenue | Share |
|---|---|---|
| Manufacturing and sale of pharmaceu | ₹0 Cr | — |
| Region | Revenue | Share |
|---|---|---|
| India | ₹181 Cr | 66.6% |
| Outside India | ₹91 Cr | 33.4% |
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹10 | 90 | 39 | 39 |
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-08-05 | Board Meetings | — |
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2026 | 0 | 0 | 0 | 3 | 0 | 4 |
| 2026 | 0 | 0 | 0 | 1 | 0 | 1 |
| 2026 | 0 | 0 | 0 | 0 | 0 | 0 |
11 recent disclosure(s)
3 disclosure(s)
📍 8th Floor Shaligram Corporates, C.J.Marg Ambli, Ahmedabad, Gujarat, 380058
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search